Alzheimer's disease — Scheltens 2016

This is an audio summary of the article “Alzheimer's Disease” by Scheltens in 2016. While dementia becomes more widespread, vascular treatments and attention to enhanced brain health have reduced its occurrence in developed countries. The most frequent cause of dementia, Alzheimer's disease, is typically diagnosed using amyloid and tau as they are cerebrospinal biomarkers. However, researchers are progressively abandoning the direct link that the detection of these proteins suggests. Their findings reveal that other factors, such as age and other physical conditions, may contribute to the development of the disease. For the diagnosis of Alzheimer's disease, well-established imaging methods include magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (PET). The clinical use of amyloid PET is expanding, although its validity and cost-effectiveness have not yet been shown. Tau PET may provide fresh perspectives and be very helpful in making a differential diagnosis and choosing people for trials. Research is increasingly focusing on the earliest stages of disease in the quest to comprehend the disease mechanism and the secrets of therapy. Preclinical Alzheimer's disease is characterized by the presence of pathological abnormalities in Alzheimer's biomarkers in people with normal cognitive function. A suitable cohort to look for preclinical Alzheimer's disease in is patients with subjective cognitive deterioration. An analysis of Alzheimer’s research reveals favorable interim outcomes for decreasing amyloid in pre-dementia patients and fairly positive results from a number of lifestyle variables as they aim to improve brain function. We go over the major advancements in Alzheimer's research in this seminar. This is the end of this informational audio track on “Alzheimer's Disease” by Scheltens.

Alzheimer’s disease. (2016, February 24). Alzheimer’s Disease - ScienceDirect. https://doi.org/10.1016/S0140-6736(15)01124-1